Hematologic Cancer Market - Trends Forecast Till 2028

Hematologic Cancer Market, By Treatment (Stem Cell Transplantation, Surgery And Radiation, Thrombosis Treatment, Anemia Treatment, Neutropenia Treatment, Others), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, T Cell Therapy), Type(Leukemia, Lymphoma, Multiple Myeloma (MM)), Stage(Stage I, Stage II, Stage III, Stage IV), Diagnosis (Bone Marrow Aspiration, Bone Marrow Biopsy), Methods (Bispecific, Antibody Drug Conjugates (ADCS), Monoclonal Antibodies, Others), Distribution Channel(Medical Stores, Hospital Pharmacies, E-Commerce Platform), End User(Hospitals, Oncology Centers, Specialty Clinics, Clinical Laboratories, Laboratory Research And Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

Published Date: September, 2020

Base Year Estimate: 2019

Report ID: D-HC-HCM-32

Format:  

Number of Pages: 321

Domain: Healthcare

Hematologic Cancer Market – Trends Forecast Till 2028

The global hematologic cancer market is anticipated to reach USD 51.6 billion by 2020 growing at a CAGR of 9.6% during the forecasting period, 2020-2028. Hematologic cancer is a disease that affects the production and function of blood cells. It has three types which are as follows leukemia, lymphoma, and myeloma. Factors such as increasing hematological cancer prevalence among the population pool and the rise in the number of premium drugs commercially are some of the major factors for the hematologic cancer market

Hematologic Cancer Market – Trends Forecast Till 2028

The global hematologic cancer market is segmented into treatment, therapy, type, stage, diagnosis, methods, distribution channel, end-users, and geography.

Treatment segment is segmented into Stem Cell Transplantation, Surgery and Radiation, Thrombosis Treatment, Anemia Treatment, Neutropenia Treatment, and Others

The therapy segment is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, and T-Cell Therapy

The type segment is segmented into Leukaemia, Lymphoma, Multiple Myeloma (MM). Leukaemia is further segmented into acute and chronic. Acute is further segmented into Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukaemia (ALL). Chronic is further segmented into Chronic Myeloid Leukaemia (CML), Chronic Lymphocytic Leukaemia (CLL). Lymphoma is further segmented into Hodgkin, Non-Hodgkin, Malignant Lymphoma, Pediatric Lymphoma. Multiple Myeloma is further segmented into Hyperdiploid (HMM), Non-Hyperdiploid and Others.

Stage segment is segmented into Stage I, Stage II, Stage III, and Stage IV

Diagnosis segment is segmented into Bone Marrow Aspiration and Bone Marrow Biopsy

Methods segment is segmented into Bispecific, Antibody Drug Conjugates (ADCS), Monoclonal Antibodies and Others

Distribution Channel segment is segmented into Medical Stores, Hospital Pharmacies and E-Commerce Platform

The end-User segment is segmented into Hospitals, Oncology Centers, Specialty Clinics, Clinical Laboratories, Laboratory Research and Clinical Trials and Others

Geographically, the global hematologic cancer market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions 

North America region is the largest contributor to the hematologic cancer market in the forecast period 2020-2028 and the Asia-Pacific region is expected to grow with the highest CAGR during the forecast period 2020-2028.

Key players in the global hematologic cancer market are Novartis International AG, Celgene Corporation, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others

The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:

  • In 2016, Novartis has announced to acquire Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD).
  • In 2015, Pfizer has announced that inotuzumab has received a breakthrough therapy designation from U.S. FDA for acute lymphoblastic leukemia

Hence, tremendous progress has been made over the last decade, and yet a lot more to come in recent years.

Available Customizations

In addition to the market data for the hematologic cancer market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirements.

Research Methodology

Secondary Research

This research method involved the usage of extensive secondary sources (such as directories and databases)—Hoovers, Avention, annual reports, investor presentation, a conference like Jefferies conference)—to identify and collect information useful for this study of the hematologic cancer market. The purpose of secondary research was to identify and collection of extensive, technical, market-oriented, and commercial studies of the global hematologic cancer market. Through secondary, the market is classified and segmented as per of industry trend, development, regional market. Product and technology development. 

Primary Research

The primary sources mainly included several industry experts from the core and related industries and suppliers, manufacturers, distributors, alliances, and organizations related to all segments of this industry’s supply chain. In-depth interviews were conducted with various primary respondents—including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts—to obtain and verify critical qualitative and quantitative information as well as to assess future prospects. The following figure depicts the market research methodology used in drafting this report on the hematologic cancer market.

The primary Respondent breakdown is provided below:

Hematologic Cancer Market – Trends Forecast Till 2028

Market Sizing

Top-down and bottom approaches were used to derive the market estimate and validate the total revenue of the hematologic cancer market. This approach has also been used to derive the market for segmentation and sub-segmentation. 

Data Validation

Impact analysis has been conducted for deriving the market size. After collecting the in-depth quantitative and qualitative data, we contact the primary respondents in order to gain a 98.8% of confidence level on our data.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants 

Reasons to Acquire

  • Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
  • Gain authentic and granular data access for the hematologic cancer market so as to understand the trends and the factors involved in changing market situations
  • Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
  • In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope

 

Report Feature

Descriptions

Market Revenue In 2020

USD 51.6 billion

Growth Rate

CAGR of 9.6% during the forecasting period, 2020-2028

Historical Data

2017-2018

Forecast Years

2020-2028

Base Year 

2019

Units Considered

Revenue in USD billion and CAGR from 2020 to 2028

Report Segmentation

Treatment, Therapy, Type, Stage, Diagnosis, Methods, Distribution Channel, End-Users, and Geography

Report Attribute

Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling

Regional Level Scope

North America, Europe, Asia-Pacific, South America, and the Middle East and Africa

Country Level Scope

U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe)

Companies Profiled

Novartis International AG, Celgene Corporation, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others

Available Customization 

In addition to the market data for the Hematologic Cancer Market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirement.

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Choose License Type
Global: 50+ Countries

Note: Report data and information will be by Country.


Regional Report

Note: Report data and information will be by Country.


Country Specific Report

Bundle Reports

50% Discount on all additional reports  

Special Pricing

Avail customised purchase options to meet your specific research requirements.

Custom Tailored Services

Delvens. offers transformed research reports where syndicated reports are not sufficient to provide solutions to your business.

Subscription Model

Get latest and trending updates throughout the year on the reports you buy.